DEVELOPMENT O F LEIDEN BIO SCIENCE PARK IN 2010

Development
of
Leiden
Bio
Science
Park
in 2010
1

Add2X Biosciences Aeon Astron Amarna Therapeutics Apotex Bab
Biocult Bioké BioPartner Center Leiden BioTop Medical BISLIFE foun
Centre for Human Drug Research ChiralVision Clinical Reach Drug De
DeltaCell Derphartox DNage Dutch Space EJR-Quartz Enzyscreen
Galapagos Genencor GiMaRIS Giotto Management Consultants HAL
Hoogheemraadschap Rijnland ISA Pharmaceuticals iSOFT Janssen Bi
Drug Research (LACDR) Leiden Bio Science Park foundation Leiden Pr
Leiden University Research & Innovation Services (LURIS) Leidse Instrum
& Health Link LSJ Medisch Projectbureau MAS International Med
Laboratory Mentor Medical Systems MEVS Millford Brand-id Mic
Nijssen Koeling OctoPlus OV BSP Pharming Group PRISNA ProFibrix Pr
Technologies ProteoNic Proxy Laboratories Questions Answers and Mo
Rivierduinen ROC Leiden Sanquin ServiceXS Servier SOFC STI Manage
Stichting Valk STRATOM Syntecnos TLC BioPharmaceuticals TNO in
School Verilabs VisiMetrix Xendo ZF-pharma ZF-Screens Zijlstr

ybloom Healthcare BAC BaseClear Batavia Bioservices BioClinica
dation Bulbfixx CAM Bioceramics Cell Signaling Technology Europe
velopment Corpus Cosine Crucell Culgi CuraRata CWTS De Stal
ExPlant Technologies Falco Biotherapeutics FlexGen Fytagoras
Allergy Heerema marine contractors Nederland Hogeschool Leiden
ologics Kenniscentrum Leiden LAP&P Leiden/Amsterdam Center for
obe Microscopy Leiden University Leiden University Medical Center
entmakers School Leyden Academy on Vitality and Ageing Development
Life Sciences
iPark MediRent Medis medical imaging systems Membrane o f Protein
rosafe Miltenyi Biotec Mymetics Nalco NCB Naturalis Leiden NewCatch
Bio
omasys Promega Prosensa Therapeutics Protein Labelling Innovation
Science
re Rahu Catalytics Rainbow Oxidations Rijnlands Revalidatiecentrum
Park
ment Stichting Contacten Bedrijfsleven Stichting Interplast in 2010 Holland
novation for life to-BBB Toko Top Institute Pharma TOPLab Hoge
a Verpakapotheek Zirkzee & Den Os Accountants Tax Lawyers ZoBio

4
Photo by Arjan van Kampenhout

Leiden Bio Science Park:
filling up
In 2010, Leiden Bio Science Park continued
to grow. The largest new acquisition for the
park is the Japanese company Astellas that
started the construction of its landmark
building for more than 500 employees in
October 2010. Also, 5 new companies established
themselves at the park, thereby
consuming all the available office and
labspace at the park. Fortunately, the
new Accelerator building was delivered
in 2010, so extra space is available now.
Additionally, the national museum of
natural history Naturalis was renamed
into the National Center for Biodiversity
Naturalis, thereby integrating all Dutch
scientific collec tions of biological species.
Altogether, Leiden Bio Science Park has been
doing very well and we hope you will enjoy
reading this overview of the latest developments
at the park.
The team of the Leiden Bio Science Park
foundation
5

NIEUW RHIJNGEEST ZUID
SNELLIUS
GORLAEUS
SYLVIUS
BOERHAAVE
ZEEZIJDE
KOP V. LEEUWENHOEK
ENTREE
BIO SCIENCE PARK
Development plan for Leiden Bio Science Park
6

Economic development
Acquisition
One of the goals of Leiden Bio Science
Park is attracting new (inter)national
companies. In order to achieve this we
closely work together with the Netherlands
Foreign Investment Agency (NFIA) and the
WestHolland Foreign Investment Agency
(WFIA). We had over 20 leads of companies
coming from the Netherlands and abroad
that were interested in establishing in the
park. Among them were a US medical device
company and an Israeli biotech company.
Together with the WFIA, Leiden Bio Science
Park also further strengthened the collaboration
with Taiwan, we visited Taiwan including
the Bio conference in July. The excellent
contacts resulted in the establishment
of TLC Biopharmaceuticals at the park. In
May 2010 Leiden Bio Science Park joined the
Holland Pavilion at BIO2010 in Chicago.
New arrivals
Leiden Bio Science Park proudly welcomed
5 new companies in 2010:
· Miltenyi Biotec moved their Benelux sales
head office and training facility from
Belgium to Leiden
· Batavia BioServices, a spin-off from TNO
· TLC BioPharmaceuticals, the Taiwanese
Liposome Company, established in Leiden
to launch their products into the European
market
· Zirkzee & Den Os Accountants Tax
Lawyers, international tax lawyers
· iSOFT, international healthcare software
developers.
Zoning plan
The new zoning plan for the Boerhaave
and Sylvius area was finalized. Consequently
the development of student housing
next to the Hogeschool Leiden could be
started. Also the city of Oegstgeest has
been working on the definitive zoning plan
for the Oegstgeest Area. The coopera tion
between the Leiden Bio Science Park
foundation and the municipality of
Oegstgeest was further strengthened by
giving a presentation for the city council.
7

Marketing & communication
In 2010 Leiden Bio Science Park was actively
networking, lobbying and intensifying
relations. The park received 41 delegations.
For example the city of Wuxi in China and the
Daegu-Gyeongbuk Free Economic Zone in
Korea visited the park to set up colla boration.
Welcome to Leiden
In September the annual Welcome to Leiden
day was organized for the employees of
newly established companies and their
families. The Leiden Bio Science Park foundation
and the city of Leiden welcomed the
families, followed by a boat tour through
the sunny canals.
Life Sciences Café
The Life Sciences Café is the monthly lively
networking event of the park. Nine Life
Sciences Café’s were held in 2010 with
presentations by newly established
com panies and presentations on a labor
flexpool, corporate finance, mobility
at the park and car sharing.
Lobby
The park informed politicians on several
subjects concerning the park, such as
the economic and societal impact of life
sciences research in Leiden and the need to
streamline regulations to the requirements
MP Elly Blanksma (middle) is shown around at Prosensa
Boat tour during Welcome to Leiden day
8

of this innovative sector. Leiden Bio Science
Park received 8 delegations of politicians
of the VVD, D66 and CDA parties from the
Dutch House of Representatives, the Senate
and the regional parliament.
Park in the press
Due to the takeover of Crucell and the
decision of Astellas to establish in Leiden,
Leiden Bio Science Park often featured in
the press. The consolidation and the related
loss of jobs in big farma led to articles about
the potential of biotech, especially of
mature clusters such as Leiden.
Social media
To promote Leiden Bio Science Park, its labor
market and collaborations, several social
media tools have been developed such as
a LinkedIn and Twitter account. Mobile
applications have been developed through
which jobs and news can be followed on
smart phones.
9

Schiphol Airport
Leiden
Delft
Oxford
Rotterdam
Life Science Zürich
Debrecen
Biocat
The Dutch Pavilion at the World Expo 2010 in Shanghai
Signing ceremony with the Yangtze River
Pharmaceutical Group
Medical Delta and HealthTIES partners
10

International connections
Leiden Bio Science Park is a proud member
of Medical Delta, the regional consortium
of Rotterdam-Delft-Leiden, focusing on
Imaging and Image-guided Medicine, Intervention
and Care and Targeted Molecular
Technology, thereby integrating the clinical
practice with engineering experience
in order to develop better products faster.
In 2010, the international connections of
Leiden Bio Science Park were intensified.
HealthTIES
Through Medical Delta, Leiden Bio Science
Park participates in the EU-Regions of
Knowledge project of HealthTIES, thereby
linking with strong life science clusters in
Oxford, Zürich, Barcelona and Debrecen.
This consortium will define optimal strategies
for cluster development.
World Expo 2010
During the World Expo 2010 in Shanghai,
Leiden Bio Science Park signed two
Memorandums of Understanding for future
collaboration. One with the Yangtze River
Pharmaceutical Group, which is currently
in the process of setting up a joint venture
with a Leiden company. This joint venture
will be located at Leiden Bio Science Park.
Furthermore, a collaboration agreement
was signed between Jiangsu Life Science
and Technology Innovation Park and Leiden
Bio Science Park, in addition to the earlier
agreement with the Shenyang European
Union Economic Development Park.
In Europe, Leiden is member of the Council
of European Biotechnology Regions and also
participates in the TechPark Alliance, linking
with parks in Germany, Belgium, Denmark,
Spain and the United Kingdom. The aim of
these international alliances is to strengthen
the collaboration and growth perspectives
of the companies in the parks.
11

Phase in pipeline
Leiden Bio
Science Park
pipeline
40
35
30
25
31
24
30
40
2009
Preclinical 16 31
Phase I 14 19
Phase II 22 24
Phase III 3 3
Pending approval 4 5
Market 30 40
20
19
22
2010
15
16
14
10
n products
5
0
Preclinical
Phase I
Phase II
3 3
Phase III
4
Pending approval
5
Market
Disease
classification
at Leiden BSP
n products
Disease area
70
60
50
40
30
20
11
10
10
9 9
6
4
0
Autoimmune
Blood & lymphatic diseases
Cancer
1
CVS
1
70 72
18
10
6 7 6 7
5 5
3 3
4
3
3
2 2
2
1
1 1
CNS
Dermatology
Digestive system
Genetic disorders
Infections
Kidneys and genito urinary system
Metabolic/endocrinology
Musculo-skeletal disorders
Respiratory system
Womens Health
Miscellaneous
0
2009
2010
Autoimmune 10 11
Blood & lymphatic diseases 6 4
Cancer 9 9
CVS 1 1
CNS 6 7
Dermatology 5 5
Digestive system 3 3
Genetic disorders 2 2
Infections 70 72
Kidneys and genito 2 1
urinary system
Metabolic/endocrinology 6 7
Musculo-skeletal disorders 10 18
Respiratory system 4 3
Womens Health 1 1
Miscellaneous 3 0
Development phase
Development
phase Leiden BSP
companies
n companies
50
40
30
20
10
0
43
Research &
discovery
45 45
35
12
Product & process
development
37
15
13 13
14 13 14
Clinical trials
Manufacturing
Distribution
35
Services
2009
2010
Research & discovery 43 45
Product & process 35 37
development
Clinical trials 13 13
Manufacturing 14 15
Distribution 13 14
Services 35 42

DEVELOPMENT OF COMPANIES
AT LEIDEN BIO SCIENCE PARK
Leiden Bio Science Park pipeline
The total number of products in the pipeline
increased from 89 in 2009 to 122 in 2010.
This increase is for products in preclinical
trials and for products in phase I. In 2010
also data from non-public companies were
added. Pharming’s Ruconest has been
accepted for the European market.
Disease classification at Leiden Bio
Science Park
The range of products under development
or on the market remained more or less
stable compared to 2009; there is still a
strong focus on infectious diseases. The large
increase in number of products in musculoskeletal
disorders is due to the development
of new products from Galapagos and
Prosensa.
Development phase
Compared to 2009, in 2010 more companies
worked on Research and Discovery. This
is due to the spin-off company NewCatch
(originating from ZF Screens) and Rahu
Catalytics which settled in the park in late
2009. The number of service companies was
strongly increased by, among others, the
arrival at the park of Batavia Bioservices,
Miltenyi Biotech and TLC Biopharmaceuticals.
13

Made in Leiden
Leiden pipeline
Companies are in different stages of bringing
their product to the market. Some highlights
of public Leiden Bio Science Park companies
are shown in the table at the next page.
14

PRECLINICAL PHASE I PHASE II PHASE III PENDING
APPROVAL
MARKET
CRUCELL
Start of discovery programs leading
to the development and commercialization
of a universal respiratory
syncytial virus (RSV) vaccine and
one program on a HPV vaccine.
Start of a Phase I clinical study in
Burkina Faso for an AdVac-based
malaria vaccine vector. Crucell also
announced the intention to participate
in a trial in the USA and Africa
in healthy adults that are not infected
with HIV for two AdVac-based AIDS
vaccine candidates.
Start of a phase II trial for the
tuberculosis (TB) vaccine candidate-
AERAS-402/Crucell Ad35 in HIV
infected adults, jointly with Aeras
Global TB Vaccine Foundation.
GALAPAGOS
First-in-human trial with candidate
drug GLPG0187 offers a new
approach to treat metastases, a
severe complication of many cancers.
Galapagos also acquired a small
molecule drug acting on arthritis from
its collaboratoin with GSK. Initiation of
a Phase I clinical trial with this selective
JAK inhibitor. In December, they successfully
completed the first-in-human
trial for GLPG0492, its candidate drug
for Cachexia.
Start of a trial for flagship program
GLPG0259, a drug being developed
for rheumatoid arthritis (RA).
MYMETICS
New preclinical trial at the University
of California for Mymetics' innovative
HIV vaccine. Another study on Respiratory
Syncytial Virus (RSV) vaccine
showed protection against a live virus
challenge.
The vaccination of human volunteers
as part of a clinical Phase I trial for
a preventative HIV vaccine has been
well tolerated. This Phase I trial follows
the breakthrough preclinical results
Mymetics has achieved in 2009.
There are also strong preliminary
results of a Phase I trial on Mymetics'
promising HIV vaccine, MYMV101.
The innovative Malaria vaccine has
successfully completed a Phase Ib
clinical trial in Tanzania and will enter
phase II. The study confirms that the
company's virosome-based vaccine is
well tolerated and safe for adults and
children as young as 5 years of age.
OCTOPLUS
Positive results from two Phase
IIb trials further demonstrating
the strong anti-viral response and
tolerability advantages of the 480 μg
dose of Locteron in the treatment of
hepatitis C.
PHARMING
Preclinical evidence that its recombinant
human C1 inhibitor (rhC1INH)
may play an important therapeutic
role in the prevention of delayed
graft function (DGF) after solid organ
transplantation.
15
Pharming and Swedish Orphan Biovitrum
(Sobi) announced that the European
Commission has granted Pharming Marketing
Authorization for its lead product
Rhucin (Ruconest) for the treatment of
acute attacks of Hereditary Angioedema
(HAE) and reported its first sales in Denmark
en Norway in December.

Business at Leiden Bio Science Park
Takeover
In December 2010, Johnson & Johnson and
Crucell announced that Johnson & Johnson
was making a recommended cash offer for
all of the issued and outstanding ordinary
shares of Crucell which led to a takeover
by Johnson & Johnson in March 2011.
2010 deals
Leiden Bio Science Park companies were
successful in closing deals. In 2010 about
40 deals were closed, we name a few:
· to-BBB made several deals. Among
them a research collaboration with
GlaxoSmithKline (GSK) involving to-BBB’s
proprietary G-Technology ® in delivering
a biological compound to the brain and
a joint program with NeuroVive Pharmaceutical
to develop therapies for stroke
and other acute neurodegenerative
diseases by combining their technologies.
· BAC extended its license agreement
with LFB Biotechnologies France, to
cover the use of BAC’s anti- Factor VIIa
CaptureSelect ® affinity ligand in the largescale
purification of recombinant human
Factor VIIa (rhFVIIa).
· ProteoNic and ORYZON Genomics joined
forces to develop new antibodies against
prostate cancer and generate cost-
Photo by Laura Vis
16

Hans GCP Schikan
CEO Prosensa
“Thanks to our strong partnerships with
patient organizations, with the LUMC and
with GlaxoSmithKline, in 2010 we again
could make great progress in our joint fight
against Duchenne Muscular Dystrophy.”
effective production-ready cell lines.
By awarding the joint venture a EuroTrans-
Bio grant, the EU recognized the unique
combination of skills that will serve an
unmet medical need for new prostate
cancer diagnostics and treatment.
· ProFibrix entered into an agreement
with CSL Behring for the clinical and
commercial supply of plasma-based
fibrinogen and thrombin, for the
manufacturing of Fibrocaps.
· Prosensa started a phase I/II clinical study
for PRO044 in patients with Duchenne
Muscular Dystrophy (DMD). Prosensa also
initiated two further programmes under
the existing alliance with GlaxoSmithKline
(GSK) covering novel RNA-based
treatments for DMD. Under the same
alliance Prosensa received a £7,5m
milestone payment from GSK as a result
of achieving a data milestone in its Phase
IIa open label extension trial of
GSK2402968 (PRO051).
· In December 2010 Leiden based biotech
company Pharming and Swedish Orphan
Biovitrum started the sale of Ruconest.
Ruconest is the first recombinant C1
esterase inhibitor for acute treatment
of angioedema attacks in patients with
Hereditary Angioedema (HAE) and the
first biotech product fully developed in
the Netherlands that reaches the market.
Photo by Laura Vis
17

The drilling of the first pillar in the presence of President and CEO of Astellas, mr. Masafumi Nogimori, the mayor of Leiden,
mr. Henri Lenferink and CEO Astellas Pharma Europe, mr Masao Yoshida (from left to right)
Artist impression of the Corpus Hotel
Artist impression of the new Wassenaarseweg student campus of Leiden University
18

Masao Yoshida
President and CEO Astellas Pharma Europe Limited
“By locating our new commercial and R&D facilities at Leiden
Bio Science park, we have placed ourselves in the heart of
a thriving scientific and medical community. We are in an
excellent position to continue our mission of discovering,
developing and marketing innovative medicines which fulfill
unmet needs and offer patients hope for a brighter future.“
Company highlights at
Leiden Bio Science Park
On October 7, the CEO of Astellas,
mr. Masafumi Nogimori, the CEO of Astellas
Pharma Europe, mr Masao Yoshida and the
mayor of Leiden, mr. Henri Lenferink,
drilled the first pillar of the new building
of Astellas. The accommodation, which
will be comple ted at the end of 2012,
will house an ultra modern laboratory for
scientific research and development and the
commercial offi ces of the company. In total
the building will be approximately 15,000
m 2 , will house over 500 employees and the
investment made is € 57,5 million.
The construction of the new Rivierduinen
building officially started on May 27. The
building, 28,000 m 2 in total, will house the
largest cluster for mental healthcare in
the Netherlands. The opening of the new
building is planned in Spring 2012.
By officially opening the NYSE Euronext
in Amsterdam on July 27, CFO Susan
Swarte and CEO Simon Sturge of OctoPlus
celebrated the anniversary of the company.
OctoPlus started their business at Leiden Bio
Science Park 15 years ago.
By digging the first hole in the ground on
July 6 2010, mayor Els Timmers–van Klink
of Oegstgeest started the building of the
Corpus Hotel. This four star hotel of the
Hilton group will be situated next to the
Corpus building. The opening is expected
in Spring 2012.
Student housing company DUWO started
the construction of the campus housing of
Leiden University. According to a special
concept more than 500 student homes are
built at the Wassenaarseweg in Leiden and
will be ready Spring 2012.
19

Expat Centre meeting The eyecatching staircase in the extension of the Hogeschool Leiden building Kids doing experiments at the Skills
Masters fair for the promotion of
laboratory professions
20

Paul van Maanen
President Hogeschool Leiden
"The new part of the building of Leiden University of Applied Sciences
was put into use at the beginning of 2010. Among other things, it is
characterized by the expansion of the amount of our laboratories.
Leiden UAS works closely with partners in the Bio Science Park en
plays a pro-active role in the realization of the knowledge center of
the region. We have grown into a serious partner in Bio Science."
Education and labor market
Human capital and a healthy labor pool at
Leiden Bio science Park are crucial for the
growth of organizations and important
factors for the establishment of new
companies. A variety of projects is conducted
in a joint effort to enhance the park’s
position at the education and labor market.
These projects involve collaborations on
either national, regional or local level and
are aimed at increasing the quantity or
quality of education and labor pool.
At Leiden Bio Science Park human capital is
more and more attracted by the recruitment
of employees beyond the national borders.
In order to help these knowledge migrants
to settle in the Leiden region, the Expat
Centre Leiden was set up. It opened its doors
on January 2010 21. The services of the
Expat Centre include providing information
on immigration formalities, living in the
region (taxes, insurances, housing and
schools) and social life. There are advisors
on banking, legal issues, taxes, insurances
and housing helping the expats with
dedicated information.
A consortium of companies and educational
organizations has worked on setting up
the Bio Simulation Factory. The business
plan of the factory was submitted (50/50
public/private financing). In addition
the consortium made a start with the
development of educational programs for
the Bio Simulation Factory where students
have the possibility to learn by doing in
a state-of-the-art pharmaceutical plant.
A flexible, regional labor pool for the
biotechnology and pharma sector was
set up in a collaboration between an
employment agency and companies. This
labor pool, named BioScience@work, fulfills
the increasing need of employers to create
flexibility by interchanging employees
during periods in which the demand for
employees strongly fluctuates. This also
helps retaining the knowledge and skills in
pharma and biotechnology for the region.
21

Facilities
The Leiden Bio Science Park shuttle bus
Excellent facilities are key assets for a
well developed cluster. In Leiden young
developing companies are supported by
shared incubation facilities at the BioPartner
Center and Leiden’s Technology Transfer
Office LURIS offers legal and business
support and access to finance.
Shared services
The association of companies at the park,
the OV BSP, provides several shared services
for the park. Examples are the car sharing
project and the shuttle bus service that
both started in 2010. The shuttle bus service
through the park fills the hard felt need for
more public transport during rush hours.
Furthermore, in 2010 the OV BSP was also
active in lobbying for the new circular road
Rijnlandroute and the lightrail connecting
the park to the region (RijnGouwelijn),
it took care of the refurbishment of the
roundabouts, the installation of new
entrance markers at the main roads and
a renewed collective security contract.
In 2010 the foundation and the OV BSP
started cooperating more intensely. The first
step was the relocation of the park manager,
Pauline Hol, to the foundation’s office at the
Poortgebouw.
BioPartner Center Leiden
The incubator BioPartner Center Leiden
received 2 new tenants in 2010, TLC
Biopharmaceuticals from Taiwan and
Leiden Probe Microscopy, a spin off
of the Science faculty of Leiden University.
In December 2010 the new Accelerator
building was completed. Several maturing
companies will move from the incubator
facilities to the new Accelerator leaving
extra space for new starting companies.
LURIS
LURIS celebrated their five-year lustrum
with the booklet ‘Focus on the Appliance of
22

Science from Leiden’, demonstrating fruitful
collaborations, highlighting successful spinoffs
and also showing how valorization
and fundamental research are mutually
beneficial partners. Worth mentioning is
the change in entrepreneurial culture in
the academic institutions achieved over the
years, as witnessed by a significant increase
in the interest in company formation.
NeCEN
In 2010, the Netherlands Centre for Electron
Nanoscopy (NeCEN) received a grant of
6,1 million euro from the Netherlands
Organization for Scientific Research (NWO).
A total of 6 million euro was donated by
various financers with the approval of a
grant application by the European Regional
Development Fund (EFRO). The first of the
two microscopes arrived in 2010 and to
house the new microscopes, expansion of
the Cell Observatory started. The centre will
open its doors in the Fall of 2011 and will
be an open access facility to support the
biomedical research of research institutes
as well as companies.
NeCEN nanomicroscope
23

People involved in the development
of Leiden Bio Science Park
Board of the Leiden Bio Science Park foundation
Willem te Beest, chairman, vice president executive board
Leiden University
Ferry Breedveld, vice chairman, chairman LUMC
Pedro Tetteroo, treasurer, coach
Marc Witteman, (thru April 2010), alderman city of Leiden
Robert Strijk, (from April 2010), alderman city of Leiden
Toon Stegmann, interim chairman entrepreneurs society OV BSP
Menzo Havenga, CEO Batavia Bioservices
Ard Tijsterman, founder Xendo Pharma Services
Advisory Board
Douwe Breimer, former president Leiden University
Ronald Brus, CEO Crucell
Sander van Deventer, general partner Forbion Capital Partners
Asje van Dijk, deputy Economic Affairs province of Zuid-Holland
Harry Flore, CEO HAL Allergy
Jacques van Gaal, (thru July 2010), president ROC Leiden
Jeff Gielen, director Kadans Biofacilities
Dick Harms, director Leiden Instrumentmakers School
René de Jong, managing director Rabobank Leiden, Leiderdorp and
Oegstgeest
Anne Willem Kist, former president Leiden University
Jeroen Knigge, (from August 2010), president ROC Leiden
Roelof Konterman, chairman Achmea Zorg
Ada Kruisbeek, scientific officer TTO VU MC / director Life Science
Center Amsterdam, founder DCPrime
Henri Lenferink, mayor city of Leiden
Paul van Maanen, president Hogeschool Leiden
Maarten van der Plas, policy advisor city of Leiden
Bas Reichert, founder and operational director BaseClear
Henri Remmers, founder Corpus Experience
Bob Smailes, managing director LURIS
Ruud van Spronsen, real estate developer PCS Design
Rein Strijker, CEO DNage
Simon Sturge, CEO OctoPlus
24

Els Timmers, mayor city of Oegstgeest
Dinko Valerio, founder Crucell, VC Aescap
Sjoerd Verduyn Lunel, dean Science faculty Leiden University
Willem van Weperen, CEO to-BBB
Office
Nettie Buitelaar, managing director
Annelieke Hoenderkamp, project manager
Hermine Klein, marketing manager
Carla van der Laan, office manager, HR consultant
Leon Mur, project manager labor market
Miranda de Regt, office manager
Ellen Smit, account manager
Pauline Hol, park manager OV BSP
Support network
Mark Bottema, province of Zuid-Holland
Adrie den Broeder, city of Leiden
Jessica Hilhorst, city of Leiden
Roel Meeuwesse, ministry of Economic Affairs,
Agriculture and Innovation
Maarten van der Plas, city of Leiden
Ronald Stokkel, city of Leiden
Dealflow meetings
Lissa Boxy and Wim Rutgers, WFIA
Annelies den Breejen, Chamber of Commerce
Adrie den Broeder, Maarten van der Plas and Jessica Hilhorst,
city of Leiden
Curt Daniels, LURIS (from October 2010)
Frans Dekker, Leiden University, real estate
Loes van Groningen, LUMC, real estate
Laura MacDonald, LURIS (until October 2010)
Laura Platte, city of Oegstgeest
Ellen Smit, Leiden Bio Science Park foundation
Henk Venema, BioPartner Center Leiden
25

Add2X Biosciences Aeon Astron Amarna Therapeutics Apotex Bab
Biocult Bioké BioPartner Center Leiden BioTop Medical BISLIFE foun
Centre for Human Drug Research ChiralVision Clinical Reach Drug De
DeltaCell Derphartox DNage Dutch Space EJR-Quartz Enzyscreen
Galapagos Genencor GiMaRIS Giotto Management Consultants HAL
Hoogheemraadschap Rijnland ISA Pharmaceuticals iSOFT Janssen Bi
Drug Research (LACDR) Leiden Bio Science Park Colofon foundation Leiden Pr
This report is published by
Leiden University Research & Innovation Services (LURIS) Leidse Instrum
the Leiden Bio Science Park
foundation.
& Health Link LSJ Medisch Projectbureau MAS International Med
Laboratory Mentor Medical Systems MEVS Millford Brand-id Mic
Nijssen Koeling OctoPlus OV BSP Pharming Group PRISNA ProFibrix Pr
Drukkerij Brummelkamp,
Technologies ProteoNic Proxy Laboratories Questions Answers and Mo
Rivierduinen ROC Leiden Sanquin ServiceXS Servier SOFC STI Manage
Stichting Valk STRATOM Syntecnos TLC BioPharmaceuticals TNO in
School Verilabs VisiMetrix Xendo ZF-pharma ZF-Screens Zijlstr
Design
ratiodesign.nl
Print
Hoofddorp
26

ybloom Healthcare BAC BaseClear Batavia Bioservices BioClinica
dation Bulbfixx CAM Bioceramics Cell Signaling Technology Europe
velopment Corpus Cosine Crucell Culgi CuraRata CWTS De Stal
ExPlant Technologies Falco Biotherapeutics FlexGen Fytagoras
Allergy Heerema marine contractors Nederland Hogeschool Leiden
ologics Kenniscentrum Leiden LAP&P Leiden/Amsterdam Center for
obe Microscopy Leiden University Leiden University Medical Center
entmakers School Leyden Academy on Vitality and Ageing Life Sciences
iPark MediRent Medis medical imaging systems Membrane Protein
rosafe Miltenyi Biotec Mymetics Nalco NCB Naturalis NewCatch
omasys Promega Prosensa Therapeutics Protein Labelling Innovation
re Rahu Catalytics Rainbow Oxidations Rijnlands Revalidatiecentrum
ment
Stichting Contacten Bedrijfsleven Stichting Interplast Holland
novation for life to-BBB Toko Top Institute Pharma TOPLab Hoge
a Verpakapotheek Zirkzee & Den Os Accountants Tax Lawyers ZoBio

www.leidenbiosciencepark.nl
Leiden Bio Science Park foundation · Rijnsburgerweg 10 · Poortgebouw Noord · 2333 AA Leiden · The Netherlands · T +31 (0) 71 524 75 55
28